Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Roter Cysticare is an orally administered medical device developed by Roter for the treatment and prevention of urinary tract infections, specifically cystitis. The product's formulation typically includes a combination of xyloglucan, gelatin (gelose), propolis, and Hibiscus sabdariffa. Its primary mechanism of action is the formation of a protective mechanical barrier in the intestinal lumen, created by the xyloglucan and gelatin components. This physical film prevents the proliferation and subsequent migration of uropathogenic bacteria, such as *Escherichia coli*, from the gastrointestinal tract to the urinary system. By addressing the gut-to-bladder migration pathway, Roter Cysticare provides a non-antibiotic approach to managing recurrent urinary tract support and infection prevention.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Roter Cysticare.